Regulatory agencies are demanding more from your PRO strategy
Both the FDA and EMA have put increased emphasis on collecting patient-reported outcome (PRO) data in oncology trials:
June 2021 – FDA’s Core PROs in Cancer Clinical Trials Guidance for Industry
- Here the FDA provides detailed guidance on what to measure with PROs, considerations for PRO selection, and how often to collect them.
June 2022 – FDA COA in Oncology Trials Industry Workshop
- The 7th annual workshop brought industry leaders together, including regulators, experts and patient advocates, to discuss emerging themes relating to the use of PROs in oncology trials.
Our free guide sets out in more detail how these regulatory developments impact your PRO strategy.
How to design a patient-centric cancer trial
Make PRO collection simple, convenient and relevant to your patients.Learn more
Differentiate your oncology drug with PROs
Stand out in a highly competitive market by capturing changes to patients’ wellbeing and quality of life.Learn more
Clario’s oncology experience